Study reveals shortfalls in federal regulatory oversight of synthetic biology output

06/3/2014 | Bloomberg BNA (free content)

New techniques in biotech and synthetic biology are leading to less federal oversight, according to a study from the J. Craig Venter Institute. The study says the federal Animal and Plant Health Inspection Service lacks the authority to review organisms synthesized using newer methods, while the Environmental Protection Agency needs more financial support and expertise to keep up with the rise of biotech organisms. The institute suggested expanding the oversight of the regulating agencies and concentrating on the plants and organisms that present more risks.

View Full Article in:

Bloomberg BNA (free content)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC